Novartis AG (NVS)
Pre-Market:
| Previous Close | 84.28 |
| Open | 83.60 |
| Bid | 84.55 x 1000 |
| Ask | 84.61 x 800 |
| Day's Range | 83.18 - 84.01 |
| 52 Week Range | 79.09 - 95.17 |
| Volume | |
| Avg. Volume | 2,400,263 |
| Market Cap | 185.518B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 7.82 |
| EPS (TTM) | 10.71 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (3.97%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | 104.40 |
- Zacks
Novartis (NVS) Announces Positive Data on Oncology Drug
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
- Zacks
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
- Bloomberg
Novartis Leaning Toward Spinoff of $25 Billion Generics Arm
(Bloomberg) -- Novartis AG is leaning toward a spinoff of its generic-drug unit, as a challenging environment for leveraged buyouts makes a potential sale to private equity more difficult, people familiar with the matter said. Most Read from BloombergUS Will Face High Gas Prices ‘as Long as It Takes,’ Biden SaysThe Wheels Have Come Off Electric VehiclesCrypto Meltdown Claims Rolex and Patek Philippe as VictimsStock Doomsayers Vindicated in Historic First Half: Markets WrapUkraine Latest: Kyiv La
